ENANTA PHARMACEUTICALS INC
Geschlossen
BrancheGesundheitswesen
13.66 -2.36
Übersicht
Veränderung der Aktienkurses
24h
Min
13.62
Max
14.54
Einkommen | -1.2M -13M |
|---|---|
Verkäufe | -1.5M 17M |
EPS | -0.451 |
Gewinnspanne | -76.292 |
Angestellte | 120 |
EBITDA | -958K -8.6M |
Empfehlungen | Buy |
|---|---|
12-Monats-Prognose | +42.25% upside |
Nächstes Ergebnis | 7. Aug. 2026 |
|---|
Marktkapitalisierung | -33M 389M |
|---|---|
Vorheriger Eröffnungskurs | 16.02 |
Vorheriger Schlusskurs | 13.66 |
Nachrichtenstimmung
By Acuity
97%
3%
322 / 342 Ranking in Healthcare
ENANTA PHARMACEUTICALS INC Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Über ENANTA PHARMACEUTICALS INC
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.